Cargando…
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials
AIMS/HYPOTHESIS: Observational and mechanistic studies have suggested a possible relationship between treatment with metformin and decreased incidence of cancer in participants with type 2 diabetes. We extracted data for malignancies from the ADOPT (A Diabetes Outcome Progression Trial) and RECORD (...
Autores principales: | Home, P. D., Kahn, S. E., Jones, N. P., Noronha, D., Beck-Nielsen, H., Viberti, G. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910882/ https://www.ncbi.nlm.nih.gov/pubmed/20532476 http://dx.doi.org/10.1007/s00125-010-1804-y |
Ejemplares similares
-
Rosiglitazone RECORD study: glucose control outcomes at 18 months
por: Home, P D, et al.
Publicado: (2007) -
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial
por: Komajda, Michel, et al.
Publicado: (2010) -
Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study
por: MacDonald, Michael R., et al.
Publicado: (2011) -
Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
por: Komajda, Michel, et al.
Publicado: (2008) -
Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT)
por: Kahn, Steven E., et al.
Publicado: (2010)